深圳华大基因股份有限公司 2024 年度独立董事述职报告 深圳华大基因股份有限公司 2024 年度独立董事述职报告（杜兰） 本人作为深圳华大基因股份有限公司（以下简称公司）的独立董事，根据《中 华人民共和国公司法》《上市公司独立董事管理办法》《上市公司独立董事履职指 引》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》（以下简称《创业板规范运作》）等法律法规及《公司章程》《独立董事制 度》等相关规定和要求，本着对全体股东负责的态度，忠实、勤勉地履行独立董事 职责，充分发挥独立性和专业性作用，切实维护公司整体利益和中小股东合法权 益。现就本人2024年度履行独立董事职责情况报告如下： 一、独立董事的基本情况 本人杜兰，中国国籍，博士、正高级经济师。现任广东爱因智能科技有限公司 董事长、世界数字科学院（World Digital Technology Academy）国际首席人工智能 官。曾任科大讯飞股份有限公司副总裁、中国移动互联网公司综合部总经理。2021 年6月起担任公司独立董事。本人具体情况详见公司《2024年年度报告》中"董事、 监事和高级管理人员情况"部分。 作为公司的独立 ...

深圳华大基因股份有限公司 2024 年度独立董事述职报告 深圳华大基因股份有限公司 2024 年度独立董事述职报告（曹亚已离任） 本人作为深圳华大基因股份有限公司（以下简称公司）的独立董事，根据《中 华人民共和国公司法》《上市公司独立董事管理办法》《上市公司独立董事履职指 引》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 （以下简称《创业板规范运作》）等法律法规及《公司章程》《独立董事制度》等 相关规定和要求，本着对全体股东负责的态度，忠实、勤勉地履行独立董事职责， 充分发挥独立性和专业性作用，切实维护公司整体利益和中小股东合法权益。本人 因第三届董事会任期届满已于2024年6月18日起卸任公司独立董事职务，现就本人 2024年度任期内履行独立董事职责情况报告如下： 一、独立董事的基本情况 本人曹亚，中国国籍，硕士，教授、博士生导师。1981年至今任职于中南大学 湘雅医学院。现任中南大学湘雅医学院肿瘤研究所教授、博士生导师，教育部癌变 与侵袭原理重点实验室学术委员会副主任，中南大学分子影像学中心学术委员会主 任，圣湘生物科技股份有限公司独立董事。2021年6月至2024年6月担任 ...

深圳华大基因股份有限公司董事会 深圳华大基因股份有限公司（以下简称公司）董事会根据《上市公司独立董 事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》等相关规定，并结合在任独立董事出具的《独立董事关于 2024 年 度独立性情况的自查报告》，就公司 2024 年末在任独立董事杜兰女士、于李胜先 生、侯志波先生的独立性情况进行评估并出具如下专项意见： 经核查独立董事杜兰女士、于李胜先生、侯志波先生的任职经历以及其签署 的相关自查文件，上述三位独立董事未在公司担任除独立董事、董事会专门委员 会委员以外的其他任何职务，也未在公司的主要股东公司担任任何职务，与公司 及其主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系， 亦不存在其他影响独立董事独立性的情况。因此，公司独立董事符合《上市公司 独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等法律法规对独立董事独立性的相关要求。 深圳华大基因股份有限公司董事会 关于 2024 年度独立董事独立性自查情况的专项意见 2025 年 4 月 24 日 ...

| 名称 持有数量(万股) | | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 深圳华大基因（300676）科技有限公司 | 14128.56 | 34.16 | -748.83 | | 深圳生华投资企业(有限合伙) | 3447.05 | 8.34 | 不变 | | 中国银行股份有限公司-华宝中证医疗交易型开放式指数 | | | | | 证券投资基金 | 814.89 | 1.97 | -21.65 | | 中国工商银行股份有限公司-易方达创业板交易型开放式 | 596.35 | 1.44 | -47.26 | | 指数证券投资基金 | | | | | 香港中央结算有限公司 | 521.97 | 1.26 | 213.00 | | 交通银行股份有限公司-万家行业优选混合型证券投资基 金(LOF) | 500.01 | 1.21 | -100.00 | | 深圳华大三生园科技有限公司 | 393.58 | 0.95 | 不变 | | 法国巴黎银行-自有资金 | 353.04 | 0.85 | 新进 | | 深圳华大基因股份有限公 ...

Financial Performance - In 2024, the company achieved operating revenue of CNY 3,866.92 million, a year-on-year decrease of 11.10%[5]. - The net profit attributable to shareholders was a loss of CNY 902.69 million, a year-on-year decline of 1,071.68%[5]. - The decline in revenue was primarily due to industry cycles and intensified market competition, leading to a significant drop in gross margins for some products[5]. - Increased R&D investment has impacted net profit due to high costs without a corresponding significant increase in revenue[5]. - The net cash flow from operating activities decreased by 76.58% to CNY 95,722,825.51 in 2024, down from CNY 408,767,851.37 in 2023[28]. - The total assets at the end of 2024 were CNY 12,542,286,394.63, a decrease of 7.87% from CNY 13,613,007,886.01 at the end of 2023[28]. - The net assets attributable to shareholders decreased by 7.35% to CNY 9,134,857,139.18 at the end of 2024, compared to CNY 9,859,237,734.19 at the end of 2023[28]. - The basic earnings per share for 2024 was CNY -2.1890, a decline of 1,066.02% from CNY 0.2266 in 2023[28]. - The diluted earnings per share for 2024 was CNY -2.1890, down 1,071.59% from CNY 0.2253 in 2023[28]. - The weighted average return on equity for 2024 was -9.50%, a decrease of 10.43% from 0.93% in 2023[28]. - The company reported a negative net profit for the most recent three accounting years, indicating uncertainty in its ability to continue as a going concern[29]. Strategic Focus and Innovation - The company plans to focus on product and technology innovation, accelerating key product iterations and new product development[7]. - The company is leveraging AI and big data to reduce testing costs and optimize channel layouts to maintain competitive advantages[7]. - Future strategic plans and risk management measures are outlined in the management discussion section of the report[7]. - The company is committed to continuous innovation in gene technology, which is recognized as a key area for future economic growth[39]. - The company is focused on leveraging AI and big data in gene technology to enhance precision medicine and health management services[39]. Market Expansion and Partnerships - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[20]. - A new partnership with Guangzhou Zhongjian Yunkang is anticipated to increase service offerings and improve customer reach[19]. - The company has established partnerships with multiple countries along the "Belt and Road" initiative, including Saudi Arabia and Uzbekistan, to enhance local healthcare services[139]. Research and Development - The company increased its R&D investment to 676.95 million yuan, representing a year-on-year growth of 10.20%[140]. - The company is focusing on the localization of raw materials for the NIFTY non-invasive prenatal testing kit to reduce costs and enhance market competitiveness[189]. - The company has launched a new spatiotemporal omics product, enhancing its capabilities in life sciences technology applications[194]. - The company has increased its R&D personnel to 711, representing a 1.14% increase from the previous year, with a higher proportion of master's and doctoral degree holders[195]. Product Development and Offerings - The company has developed a comprehensive database, "Wanshang Database," to support its genetic testing business, covering key areas such as reproductive health, tumor diagnosis, and infection prevention[99]. - The company has launched a cervical cancer DNA methylation detection product, significantly improving the specificity of high-risk HPV screening management[149]. - The company has developed a non-invasive prenatal screening (NIPT) product that can detect both maternal genetic disease-causing genes and fetal chromosomal abnormalities from a single blood sample, significantly enhancing detection performance[143]. - The company is focusing on developing a comprehensive solution for assisted reproduction, enhancing performance and reducing costs through innovative technology[143]. Regulatory Compliance and Certifications - The company has received ISO/IEC 27001:2022 certification, becoming the first in the high-throughput gene sequencing industry to achieve this international standard[132]. - The company has obtained medical device registration certificates for three products, including a gene sequencer and two software applications for genetic testing[200]. - The company has received regulatory approvals for its colorectal cancer detection product in multiple countries, establishing a solid foundation for its global market presence[107]. Market Trends and Projections - The global gene testing market is projected to grow from 19.66 billion USD in 2024 to 32.83 billion USD by 2029, with a CAGR of 10.81%[40]. - China's gene testing market is entering a high growth phase, driven by a large population base and increasing health awareness[40]. - The cancer screening market was valued at approximately $172.3 billion in 2022 and is expected to grow to $293.6 billion by 2030, indicating significant growth potential in the industry[48]. - The global digital health market is projected to reach approximately $296.46 billion in 2024, with a compound annual growth rate (CAGR) of 17.2% expected until 2029, highlighting the vast potential of multi-omics big data services in the health sector[59]. Operational Efficiency and Cost Management - The company has implemented a supply chain management system to enhance procurement efficiency and ensure product quality through a rigorous supplier evaluation process[79]. - The production model includes clinical development and application services, ensuring product quality through strict quality control processes at key production stages[81]. - The company has implemented security measures for the OmicsDB platform, including classification, auditing, encryption, and desensitization of stored data, ensuring data safety and compliance[101]. Customer Engagement and Service Delivery - The company has established medical device operation centers in over ten provinces in China and international locations, enhancing its global service capabilities[84]. - The company has launched a series of rapid testing products for home use, including COVID-19 antigen test kits and influenza virus antigen test kits, to meet the demand for quick pathogen identification[110]. - The company has trained approximately 113 hospitals on high-throughput sequencing data analysis and interpretation, covering fertility, oncology, and infection products[118].

Financial Performance - The company's revenue for Q1 2025 was ¥671,910,156.79, representing a decrease of 18.18% compared to ¥821,250,378.55 in the same period last year[2]. - The net profit attributable to shareholders was a loss of ¥52,695,120.08, a decline of 524.87% from a profit of ¥12,402,522.05 in the previous year[2]. - The net cash flow from operating activities was -¥397,093,777.71, a decrease of 422.92% compared to -¥75,937,361.58 in the same period last year[2]. - The basic earnings per share were -¥0.1278, down 521.78% from ¥0.0303 in the same period last year[2]. - The decline in performance was primarily due to a decrease in revenue scale and slower-than-expected collection of accounts receivable, leading to increased credit impairment losses compared to the previous year[10]. - Total operating revenue for the current period is ¥671,910,156.79, a decrease of 18.2% from ¥821,250,378.55 in the previous period[24]. - Net profit for the current period is a loss of ¥55,295,405.94, compared to a profit of ¥12,150,258.43 in the previous period[25]. - The basic earnings per share for the current period is -0.1278, compared to 0.0303 in the previous period, indicating a significant decline[25]. Assets and Liabilities - The total assets at the end of the reporting period were ¥12,595,327,557.05, an increase of 0.42% from ¥12,542,286,394.63 at the end of the previous year[2]. - Total liabilities increased to ¥3,360,188,917.99 from ¥3,270,676,576.56, marking a rise of 2.7%[23]. - The company’s total equity stands at ¥9,235,138,639.06, slightly up from ¥9,271,609,818.07 in the previous period[23]. - The company's total current assets amounted to RMB 6,888,220,016.77, slightly up from RMB 6,875,791,256.55 at the beginning of the period[21]. - The company's fixed assets increased to RMB 2,601,833,058.56 from RMB 2,578,695,623.85[21]. Cash Flow - The company's cash flow statement indicates a need for improved cash management strategies, as indicated by the current financial performance[27]. - Operating cash inflow for the current period was $652.49 million, down from $777.11 million in the previous period, representing a decrease of approximately 16.06%[28]. - Net cash flow from operating activities was -$397.09 million, compared to -$75.94 million in the previous period, indicating a significant decline[28]. - Cash inflow from investment activities totaled $1.84 billion, an increase from $1.08 billion in the prior period, reflecting a growth of about 70.38%[28]. - Cash inflow from financing activities was $570.96 million, a substantial increase from $32.40 million in the previous period, marking a growth of approximately 1,661.73%[29]. - The ending cash and cash equivalents balance was $2.63 billion, down from $2.91 billion in the previous period[29]. - The company experienced a negative net increase in cash and cash equivalents of -$68.26 million, compared to -$644.24 million in the previous period, indicating an improvement[29]. Shareholding Structure - As of the report date, the controlling shareholder, Huada Holdings, and its concerted parties held 147,759,217 shares, accounting for 35.53% of the total share capital[13]. - A total of 10,484 million shares held by the controlling shareholder were pledged, representing 70.95% of their holdings and 25.21% of the total share capital[13]. - Huada Holdings transferred 10.5% of its equity to a company wholly owned by the actual controller, Wang Jian, resulting in an increase in Wang Jian's direct and indirect shareholding from 31.90% to 35.75%[14]. - The overall shareholding and voting rights of Huada Holdings and its concerted parties remained unchanged at 37.34%[14]. - The company’s major shareholders include Shenzhen Huada Gene Technology Co., Ltd. with 141,285,593 shares and Shenzhen Huada San Shengyuan Technology Co., Ltd. with 34,470,455 shares[12]. - The company has not disclosed any significant changes in the shareholding structure of the top 10 shareholders due to margin trading activities[10]. - The controlling shareholder, BGI Holdings, plans to reduce its stake by up to 8,316,432 shares (2% of total share capital) from December 17, 2024, to March 16, 2025[15]. - BGI Holdings has already reduced its stake by 7,488,300 shares (1.8008% of total share capital) between March 11 and March 14, 2025[15]. - After the reduction, the combined shareholding of BGI Holdings and its concerted parties decreased from 37.34% to 35.53%, without changing the company's control[15]. Research and Development - The company reported a significant increase in research and development expenses, totaling ¥117,331,387.43, up from ¥106,372,298.63 in the previous period, reflecting a growth of 11.5%[24]. - The company has not reported any new product developments or market expansion strategies in the current period[10]. Government Subsidies - The company received government subsidies amounting to ¥2,997,389.85 during the reporting period[3]. Investment Income - The investment income increased by 374.19% to ¥3,416,203.88 from a loss of -¥1,245,924.99 in the previous year[7].

华大基因（300676）公告，2025年第一季度营业收入6.72亿元，同比下降18.18%。净亏损5269.51万 元，去年同期净利润1240.25万元。 ...

Group 1 - The Alzheimer's concept sector rose by 1.30%, ranking 6th among concept sectors, with 21 stocks increasing in value [1][2] - Notable gainers in the sector included Jinkai Biotechnology with a 20% limit-up, Shuangcheng Pharmaceutical also hitting the limit-up, and LuKang Pharmaceutical, Fujilai, and Dongcheng Pharmaceutical with increases of 3.95%, 3.60%, and 2.06% respectively [1][2] - The sector experienced a net inflow of 250 million yuan from main funds, with Shuangcheng Pharmaceutical leading the inflow at 181 million yuan [2][3] Group 2 - The top stocks by net inflow ratio included Jinkai Biotechnology at 33.12%, Shuangcheng Pharmaceutical at 19.33%, and Chitianhua at 5.51% [3] - The trading volume and turnover rates for key stocks in the Alzheimer's concept were significant, with Shuangcheng Pharmaceutical showing a turnover rate of 23.40% and Jinkai Biotechnology at 23.43% [3] - Decliners in the sector included NuoVizon, Dean Diagnostics, and BGI Genomics, with declines of 2.96%, 2.68%, and 1.85% respectively [1][4]

Core Insights - The genetic screening testing market for preventive health is experiencing rapid growth due to technological advancements, increased consumer interest in personalized medicine, and a rise in preventive healthcare strategies [2][3][5]. Market Overview - The market is driven by improvements in genetic testing technologies, such as next-generation sequencing (NGS), which have made tests more accessible, cost-effective, and accurate [3][5]. - Growing consumer awareness of early detection benefits, rising healthcare costs, and a focus on prevention are fueling demand [3][6]. Market Dynamics - The increasing availability of direct-to-consumer genetic tests empowers individuals to manage their health and gain insights into genetic predispositions [4][5]. - Stakeholders include genetic testing companies, healthcare providers, hospitals, diagnostic laboratories, and wellness organizations [4]. Regional Analysis - North America holds the largest market share, driven by technological advancements and high consumer awareness, with the U.S. being a key player [8]. - Europe is characterized by high demand for genetic tests related to cancer and cardiovascular diseases, with significant investments in preventive healthcare [9]. - The Asia-Pacific region is experiencing significant growth due to rising healthcare awareness and investment in healthcare infrastructure, with China and India emerging as key markets [10]. - The Middle East and Africa show emerging opportunities for genetic screening, particularly in the UAE, Saudi Arabia, and South Africa [11]. Competitive Landscape - Key players in the market include Exact Science, Labcorp Genetics Inc., Blueprint Genetics, Ambry Genetics, and others [7]. - The competitive landscape is marked by strategies such as funding activities, mergers and acquisitions, regulatory approvals, and partnerships [18].

Core Points - Microsoft has ceased providing Office 365 services to Chinese gene research company BGI, including essential applications like Word, PowerPoint, and Excel, as reported by Japanese media [1][2] - BGI is transitioning to domestic software solutions, specifically WPS, and has instructed employees to back up data from Microsoft services [1][2] - The cessation of services is part of a broader trend of Microsoft reducing its operations in China, with reports of layoffs at its joint venture, Wicresoft [3][4] Group 1: Microsoft Services Impact - BGI employees reported being unable to access Office 365 services as of April 3, leading to urgent data backups [2] - Microsoft has also stopped providing AI services, including GitHub Copilot and OpenAI's GPT, to BGI [2] - The company’s stock fell by 13% following the news of service termination and ongoing geopolitical tensions [2] Group 2: Microsoft Operations in China - Microsoft has confirmed it will not stop operations in China, despite rumors of a complete withdrawal [3][4] - Wicresoft, Microsoft's first joint venture in China, is reportedly facing significant layoffs, affecting nearly 2,000 employees [4] - Microsoft has previously reduced its engineering presence in China, with revenue from the region accounting for approximately 1.5% of its total income [5] Group 3: Market Dynamics - Despite a low revenue share, Chinese enterprises have been significant contributors to Microsoft's cloud growth, particularly through Azure OpenAI services [6] - The ongoing geopolitical tensions and "decoupling" movements are expected to accelerate the localization of software solutions in China [6] - Microsoft’s stock has been negatively impacted by these developments, with a notable drop in market value [6]